Aligos Therapeutics Inc’s Shares Reel: 33.82% Quarterly Revenue Decline Amid 71.15M Market Cap

The market performance of Aligos Therapeutics Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $1.76 on 03/01/23, while the lowest value for the same duration was $0.54 on 10/24/23.

52-week price history of ALGS Stock

Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Aligos Therapeutics Inc’s current trading price is -48.30% away from its 52-week high, while its distance from the 52-week low is 68.89%. The stock’s price range during the 52-week period has remained between $0.54 and $1.76. In the Healthcare sector, the company’s shares saw a trading volume of around 1.35 million for the day, which was evidently higher than the average daily volume of 0.37 million over the past three months.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Market Capitalization and Financial Performance: An In-Depth Look

Aligos Therapeutics Inc (ALGS) has experienced a quarterly rise of 33.82% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 71.15M and boasts a workforce of 83 employees.

Making Sense of Trading Volume and Moving Average Data

Based on Barchart.com data, the company’s moving average over the 100-day period was 0.6926, with a change in price of +0.1100. Similarly, Aligos Therapeutics Inc recorded 276,262 in trading volume during the last 100 days, posting a change of +13.75%.

Examining ALGS’s Debt-to-Equity Ratio: What You Need to Know

The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for ALGS stands at 0.21. Similarly, the long-term debt-to-equity ratio is also 0.16.

ALGS Stock Stochastic Average

Aligos Therapeutics Inc’s raw stochastic average for the past 50 days is presently 89.63%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 87.91%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 74.23% and 58.35%, respectively.

ALGS Stock Price Performance Analysis

Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. This year’s metric has recorded a Price increase of 37.05%. However, over the past six months, we’ve seen a weaker performance of 4.67%. The price of ALGS fallen by 30.00% over the last 30 days. And in the last five days, it has surged by 40.00%.

On Key

Related Posts